EUVIMEDEUVIMED entdecken
Crossref

Impact of Etiology and Lead Time to Treatment with First-Line Agents on Outcome of Infantile Epileptic Spasms Syndrome: A Retrospective Cohort from Low- and Middle-Income Country

Shravani Krishna Goparaju iD, Bidisha Banerjee iD, Ullas V Acharya, Mitesh Shetty

Neuropediatrics · 30.10.2026

DOI: 10.1055/a-2987-4550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropediatrics, online erschienen am 30.10.2026. Verfasst von Shravani Krishna Goparaju und 3 weiteren Autor:innen. Beteiligte Einrichtung: Manipal Hospital, Department of Paediatric Neurology, Karnataka, India, Bengaluru. Die Arbeit nennt 33 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of this study is to analyze the etiological spectrum, safety and effectiveness of first-line agents, and developmental outcomes of children with infantile epileptic spasms syndrome (IESS) managed at a tertiary-care hospital in South India, focusing on the influence of lead time to treatment. This retrospective cohort study included 65 children diagnosed with IESS between 2020 and 2025. Lead time to treatment was categorized as ≤ 1, 1 to 2, 3 to 8, and > 8 weeks. First-line therapies included high-dose oral corticosteroids, vigabatrin, or sequential therapy. Treatment response was assessed at 1 and 3 months and developmental outcomes at follow-up. The median age at onset of spasms was 6 months (interquartile range [IQR]: 5, 8), and the median treatment lag 4 weeks (IQR: 1, 12) with only 26% treated within the first week. Structural-acquired etiologies predominated (36/65; 55.3%), commonly periventricular leukomalacia (24.6%) and neonatal hypoglycemic brain injury (13.8%). Spasm cessation occurred in 62% at 1 month and was sustained in 55.4% at 3 months, with a relapse rate of 15.4%. High-dose oral corticosteroids achieved a significantly higher 1-month response than vigabatrin or sequential therapy (p = 0.006). Earlier treatment showed numerically better responses without statistical significance. Adverse effects occurred in 48%, most commonly irritability (64.5%) and weight gain (22.5%). At a mean follow-up of 19.4 months, approximately one-third of children achieved normal or borderline developmental outcomes. Structural-acquired etiologies predominated, and lead time did not significantly influence treatment response. Our findings support that high-dose oral corticosteroids appear to be an effective, practical, and reasonably safe first-line therapy for IESS in resource-limited settings.

Autor:innen und Institutionen

  • Manipal Hospital, Department of Paediatric Neurology, Karnataka, India, Bengaluru.
  • Manipal Hospital, Department of Neuro-Radiology, Karnataka, India, Bangalore.
  • Manipal Hospital, Department of Medical Genetics, Karnataka, India, Bengaluru.

ORCID-Profile: Shravani Krishna Goparaju, Bidisha Banerjee

Zitieren

APA

Krishna Goparaju, S., Banerjee, B., Acharya, U. V., & Shetty, M. (2026). Impact of Etiology and Lead Time to Treatment with First-Line Agents on Outcome of Infantile Epileptic Spasms Syndrome: A Retrospective Cohort from Low- and Middle-Income Country. Neuropediatrics. https://doi.org/10.1055/a-2987-4550

Vancouver

Krishna Goparaju S, Banerjee B, Acharya UV, Shetty M. Impact of Etiology and Lead Time to Treatment with First-Line Agents on Outcome of Infantile Epileptic Spasms Syndrome: A Retrospective Cohort from Low- and Middle-Income Country. Neuropediatrics. 2026. doi:10.1055/a-2987-4550

BibTeX
@article{KrishnaGoparaju2026,
  author = {Krishna Goparaju, Shravani and Banerjee, Bidisha and Acharya, Ullas V and Shetty, Mitesh},
  title = {Impact of Etiology and Lead Time to Treatment with First-Line Agents on Outcome of Infantile Epileptic Spasms Syndrome: A Retrospective Cohort from Low- and Middle-Income Country},
  journal = {Neuropediatrics},
  year = {2026},
  doi = {10.1055/a-2987-4550}
}
Kostenlos starten →